Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 1;64(4):374-81.
doi: 10.1097/QAI.0b013e3182a7adb2.

Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy

Carla E Ransom  1 , Yanling Huo, Kunjal Patel, Gwendolyn B Scott, Heather D Watts, Paige Williams, George K Siberry, Elizabeth G Livingston; P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Collaborators, Affiliations

Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy

Carla E Ransom et al. J Acquir Immune Defic Syndr. .

Abstract

Objective: To determine whether maternal use of tenofovir disoproxil fumarate for treatment of HIV in pregnancy predicts fetal and infant growth.

Methods: The study population included HIV-uninfected live-born singleton infants of mothers enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group protocol P1025 (born 2002-2011) in the United States and exposed in utero to a combined (triple or more) antiretroviral regimen. Infant weight at birth and 6 months was compared between infants exposed and unexposed to tenofovir in utero using 2-sample t test, χ test, and multivariable linear and logistic regression models, including demographic and maternal characteristics.

Results: Among 2025 infants with measured birth weight, there was no difference between those exposed (N = 630, 31%) versus unexposed to tenofovir in mean birth weight (2.75 vs. 2.77 kg, P = 0.64) or mean gestational age- and sex-adjusted birth weight z-score (WASZ) (0.14 vs. 0.14, P = 0.90). Among 1496 infants followed for 6 months, there was no difference in mean weight at 6 months between tenofovir-exposed (N = 457, 31%) and tenofovir-unexposed infants (7.64 vs. 7.59 kg, P = 0.52) or in mean WASZ (0.29 vs. 0.26, P = 0.61). Tenofovir exposure during the second/third trimester, relative to no exposure, significantly predicted underweight (WASZ < 5%) at age 6 months [odds ratio (95% confidence interval): 2.06 (1.01 to 3.95), P = 0.04]. Duration of tenofovir exposure did not predict neonatal or infant growth.

Conclusions: By most measures, in utero exposure to tenofovir did not significantly predict infant birth weight or growth through 6 months of age.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram
See this image and copyright information in PMC

References

    1. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005 Feb 1;40(3):458–465. - PubMed
    1. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484–494. - PubMed
    1. [Accessed 4/10/13];Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. 2012 Jul 31; http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.
    1. World Health Organization [Accessed 3/08/13];ANTIRETROVIRAL DRUGS FOR TREATING PREGNANT WOMEN AND PREVENTING HIV INFECTION IN INFANTS: Recommendations for a public health approach-2010 version. 2010. http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf. - PubMed
    1. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. http://aidsinfo.nih.gov/guidelines. - PubMed

Publication types

MeSH terms